The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study However, hypercalcemia and hypophosphatemia are both common complications after renal transplantation. Prospective observation of these complications has not been well described and pre-transplant predictors also remain unknown. This prospective observational cohort study was carried out to clarify pre-transplant risk factors of persistent hypophosphatemia and/or hypercalcemia at 12 months after transplantation. Methods. Consecutive living donor KTx recipients (n ¼ 39) at Tokyo Women's Medical University were prospectively recruited. Parameters of bone and mineral metabolism including intact parathyroid hormone (iPTH) and full-length fibroblast growth factor (FGF) 23 were followed. Results. FGF23 decreased to comparable levels for renal function while hyperparathyroidism persisted at 12 months after transplantation. Multivariate linear regression analysis revealed that pre-transplant iPTH correlated with hypercalcemia at 12 months and pre-transplant FGF23 was the best pre-transplant predictor of persistent hypophosphatemia at 12 months. Conclusions. It is intriguing that although FGF23 is not a causal factor for hypophosphatemia at 12 months posttransplantation, it is a significant predictor of this common complication.
Introduction
Recipients of kidney transplantation (KTx) have been known to develop mineral and bone disorders (MBDs) such as hypercalcemia and hypophosphatemia because most recipients continue to have significantly depressed kidney function corresponding to chronic kidney disease (CKD) Stage 3T or more and some of the immunosuppressive medications affect mineral and bone homeostasis.
Hypercalcemia is a very common complication after KTx and persistent hyperparathyroidism (HPT) has been reported to be the most plausible cause. This complication can be severe enough to cause calciphylaxis leading to renal failure, as has been reported, eventually requiring parathyroidectomy [1, 2] . Hypophosphatemia, mainly due to reduced tubular phosphate reabsorption, is also a common complication occurring in up to 93% of kidney recipients at an early stage [3] . Furthermore, serum phosphate level in patients receiving KTx remains low compared to that in non-transplant patients with CKD matched for glomerular filtration rate (GFR) [4] . Recently, fibroblast growth factor (FGF) 23 has been shown to induce hypophosphatemia due to impaired tubular phosphate reabsorption especially in the early stage of KTx [5] . After 12 months, however, renal phosphate wasting and high FGF23 has been reported to recover in most patients [4] , although hypophosphatemia may exist even 10 years after transplantation [6] .
To our knowledge, there are no prospective studies that have measured FGF23 and tried to clarify the pre-transplant risk factors for hypercalcemia and hypophosphatemia 12 months after KTx. Identifying the risk factors could lead to the prevention of these detrimental complications.
The aim of the present study was to identify the pretransplant risk factors that could predict persistent hypercalcemia, hypophosphatemia and HPT at 12 months after transplantation.
Materials and methods

Study design and population
The present study is a prospective observational cohort study of living donor KTx recipients conducted in a single center. All consecutive recipients who underwent kidney transplant at the Department of Surgery, Kidney Center, Tokyo Women's Medical University between April 2007 and March 2008 were recruited. Those who gave consent to participate in the study and were not on dialysis at 12 months post-transplantation were included in the study (n ¼ 39). Written informed consent was obtained from all participants. The procedures were in accordance with the ethical standards of the Helsinki Declaration.
Procedures, assays and calculations
Non-fasting serum samples were collected within 1 week before transplantation (pre) and at 12 months (m) post-transplantation. Spot urine samples were collected at the same time except for pre-transplantation.
Serum full-length FGF23 levels were determined with a sandwich enzyme-linked immunosorbent assay (Kainos Laboratories, Inc., Tokyo, Japan) [7] . Previous studies indicated that patients with CKD Stage 3 show FGF23 levels of 45.6 AE 23.6 pg/mL [8] . Serum 1,25(OH) 2 D (1,25D) levels were determined by radioimmunoassay; (Immunodiagnostic Systems Ltd, Boldon, England) and serum intact parathyroid hormone (iPTH) levels by electro-chemiluminescence immunoassay; (Roche Diagnostics K.K, Tokyo, Japan). Serum and urine creatinine, calcium (Ca) and phosphate (Pi) were measured using standard methods. Measured Ca levels were adjusted to albumin levels using the Payne's equation; i.e. corrected Ca (cCa) ¼ Ca 1 [4.0 À Alb (g/dL)] if serum albumin was <4 g/dL. Reference levels of 2.4-4.3 mg/dL and 8.5-10.2 mg/dL were used for Pi and cCa. Estimated GFR was calculated using the short Modification of Diet in Renal Disease formula. A measure of renal Pi handling was evaluated by the tubular maximum reabsorption of Pi corrected for GFR (TmP/GFR).
Kidney transplantation protocols
The immunosuppressive protocol was as follows; all patients received induction therapy with basiliximab. ABO-incompatible donors underwent desensitization with plasmapheresis until pre-transplant ABO titers became <16 and splenectomy was performed at the time of transplantation except for two patients who received rituximab. Intravenous methylprednisolone was administered at a dose of 500 mg for ABO-incompatible transplant and 250 mg for ABO-compatible transplant at the time of transplantation. Maintenance immunosuppression therapy consisted of corticosteroids, calcineurin inhibitors [cyclosporine (CYA) or tacrolimus ( Tac)] and antimetabolites [mycophenolate mofetil (MMF) or mizoribine]. Corticosteroid withdrawal in the second week was tried in ABO-compatible patients unless rejection was suspected or diagnosed by biopsy. Dose of CYA and Tac was adjusted by blood levels of these drugs according to standard protocols. All rejection episodes were successfully treated with a high dose of corticosteroids. All recipients stopped any Pi binders or active vitamin D 3 analogues at the time of transplant.
Statistical analysis
Data are expressed as mean AE SD or median (interquartile range) and P < 0.05 is regarded as significant. Difference between groups was calculated by the Wilcoxon rank sum test or paired or unpaired Student's t-test when appropriate. Simple linear regression analysis was used to examine the associations between the parameters. iPTH and FGF23 were logarithm (Ln) transformed for the regression analysis. Multivariate stepwise linear regression analysis was performed including all univariately associated variables (P < 0.05). The computations were carried out on the JMP version 7.0 software program.
Results
Patient characteristics
The characteristics of the study population before and at 12 months after KTx are presented in Table 1 . Most patients were taking either Ca-containing phosphate binders and/or active vitamin D 3 analog at the time of transplantation, but none received cinacalcet. Two patients received bisphosphonate, 31 received Ca-containing Pi binders and 21 received active vitamin D 3 analogues. Twenty-nine patients were still taking a corticosteroid as maintenance immunosuppression at 12 months. All the patients were on a calcineurin inhibitor [CYA 28 patients, Tac 11 patients] and antimetabolite (MMF 37 patients, mizoribine 2 patients) therapy at 12 months. All the parameters showed significant changes after KTx. FGF23 showed a marked decrease [FGF 23 before KTx versus FGF23 at 12 months after KTx; 5190.0 (605.0-17300.0) pg/mL versus 55.0 (45.0-71.0) pg/mL, P < 0.01] reaching almost similar levels to those in previously reported patients with CKD Stage 3 [8] . On the other hand, iPTH showed a significant but milder reduction [iPTH before KTx versus iPTH at 12 months after KTx; 252.0 (88.0-399.0) pg/mL versus 107.0 Figure 1 shows Pi, cCa, LnPTH and LnFGF23 data of each patient before and 12 months after KTx. The decrease in Pi and increase in cCa was observed in almost all patients and FGF23 decreased to <100 pg/mL in most patients. However, PTH levels were more variable at 12 months post-KTx.
Pre-transplant risk factors of hypophosphatemia at 12 months post-transplant Table 2 demonstrates pre-transplant factors associated with serum phosphate at 12 months. In the multivariate model, LnFGF23 and age at the time of transplantation were related to lower phosphate levels at 12 months. We have also conducted the analysis only in subjects who were not taking active vitamin D 3 analogs, calcium salts and bisphosphonates after KTx (n ¼ 34). In this analysis, LnFGF23 pre (P < 0.001), age (P < 0.01) and use of Ca-containing Pi binders (P < 0.05) at the time of transplantation were related to lower phosphate levels at 12 months.
Pre-transplant risk factors of hypercalcemia at 12 months post-transplant Table 3 demonstrates pre-transplant factors associated with serum cCa at 12 months. In the multivariate model, LnPTH pre, months on dialysis and female sex were related to higher cCa. When patients were divided into hypercalcemic (n ¼ 8) and normocalcemic (n ¼ 31) groups at 12 months, pre-transplant iPTH levels were 412.5 (322.5-750.5) pg/mL and 223.0 (87.0-341.0) pg/mL, respectively (P < 0.05). Similarly, durations on dialysis in the two groups were 127.1 (50.5-179.8) months and 30.6 (14.4-70.5) months, respectively (P < 0.01). In a multivariate analysis excluding patients given agents that affect mineral metabolism after KTx (n ¼ 34), LnPTH pre (P < 0.001) and months on dialysis (P < 0.01) were related to hypercalcemia at 12 months.
Discussion
Kidney transplantation recovers many of the functions of the kidney thereby providing better morbidity and mortality compared to a state of end-stage renal disease. However, in the case of CKD-MBD, KTx does not always seem to be an ideal ameliorating treatment. Acute or chronic post-transplant hypophosphatemia may cause detrimental effects. In the early post-transplant period, when serum phosphate is the lowest, muscle weakness may appear [9] , whereas effects of chronic hypophosphatemia are less clear. However, post-transplant bone disease is becoming a well-recognized entity, and partial involvement of hypophosphatemia has been suggested to affect bone mineralization [10] . Hypophosphatemia is reported to be present in as many as 90% of post-transplant patients [3] . Although hypophosphatemia is usually seen in the early stage after transplantation, phosphate level remains low for a long time compared to that of CKD patients matched for GFR [4] . Persistent HPT has long been suggested to be the cause of hypophosphatemia. However, inappropriate urinary phosphate wasting has been reported to occur despite low levels of PTH [11, 12] . Since FGF23 levels at 12 months post-transplant were relatively low [8] and iPTH levels were comparably high relative to GFR, pathogenesis of hypophosphatemia at 12 months may be due largely to persistent HPT rather than due to high FGF23 level. It could also be interpreted that FGF23 remains inappropriately elevated especially in light of the low serum phosphorus and decreased urinary phosphate reabsorption, thus, dysregulation of the FGF23, Pi and PTH axis may be present. The intriguing finding in this study is that pre-transplant FGF23 was the best predictor of hypophosphatemia at 12 months. In one report, FGF23 has been shown to effectively predict future development of refractory secondary HPT in long-term dialysis patients [13] . High FGF23 has also been suggested to predict poor response to active vitamin D 3 treatment [14] . Therefore, it is possible that subjects who required higher doses of active vitamin D3 to control secondary hyperparathyroidism showed more elevated FGF23 before KTx because 1,25(OH) 2 D is known to stimulate FGF23 production. However, unfortunately it was not possible to accurately evaluate the doses of active vitamin D 3 analogs in this study because several medications with different methods of administration were used in these patients. Further study is necessary to clarify why FGF23 value before KTx predicts future hypophosphatemia. Even more influential on mortality and morbidity may be long-lasting hypercalcemia, which is considered to be a risk factor for calciphylaxis and renal dysfunction [15, 16] . As seen from our results, post-transplant hypercalcemia is largely influenced by pre-transplant iPTH. Actually, in this study, hypercalcemic and normocalcemic patients at 12 months had pre-transplant iPTH of 412.5 (322.5-750.5) pg/mL and 223.0 (87.0-341.0) pg/mL, respectively. Factors such as dialysis duration and female sex also correlate are needed with a hypercalcemia, as depicted by previous reports [1, 17, 18] .
It would be useful if we could predict future hypophosphatemia and/or hypercalcemia. If so, we may be able to take actions such as strict medical or surgical control of HPT before or after transplantation to avoid the detrimental effects of hypophosphatemia and hypercalcemia. The role of FGF23 as an indicator of post-transplant CKD-MBD has not been evaluated extensively [19] . From this study, it could be postulated that interventions to lower FGF23, iPTH and cCa at the time of dialysis would prevent hypophosphatemia and/or hypercalcemia after KTx.
The limitation of this study is that it was a study with a small number of subjects and further studies are needed with a larger number of patients. The study did not include a control group adjusted for stimated estimated GFR so therefore, CKD-MBD parameters were compared with those in previously reported papers. There were patients with variable pre-and post-transplant medications in routine patient care, reflecting the actual clinical scene. Although the dose of pretransplant medications, which could affect mineral metabolism, such as active vitamin D 3 , was not analyzed due to the wide variety of doses and routes of administration, not many studies have evaluated pre-transplant medication as a considerable risk factor as we have done in this study. This study is also unique in that the cohort was a homogeneous cohort consisting of living donor KTx only. Larger studies including cadaveric donor KTx would be needed to further confirm this phenomena in the more general KTx population.
Conclusion
This study identified pre-transplant FGF23 and iPTH to be the best predictor of persistent hypophosphatemia and hypercalcemia at 12 months after KTx. 
